Patents Assigned to Viral Antigens, Inc.
  • Specificity in the detection of anti-rubella IGM antibodies
    Patent number: 6872396
    Abstract: This invention particularly discloses an improved immunoassay method for the specific detection of anti-rubella IgM antibodies. This method employs rubella antigens comprising rubella E1 and E2 envelope glycoproteins substantially free of capsid protein. Use of this antigen composition reduces or eliminates nonspecific protein-protein interactions leading to false positive results. A sample diluent comprising urea can also be used in the process to further reduce the occurrence of nonspecific protein-protein interactions. A diagnostic kit to aid in the detection of anti-rubella IgM antibodies is also disclosed.
    Type: Grant
    Filed: October 29, 2003
    Date of Patent: March 29, 2005
    Assignee: Viral Antigens, Inc.
    Inventors: Preston H. Dorsett, Frances I. Byrd, Robert F. Devlin
  • Specificity in the detection of anti-rubella IgM antibodies
    Patent number: 6670117
    Abstract: This invention particularly discloses an improved immunoassay method for the specific detection of anti-rubella IgM antibodies. This method employs rubella antigens comprising rubella E1 and E2 envelope glycoproteins substantially free of capsid protein. Use of this antigen composition reduces or eliminates nonspecific protein-protein interactions leading to false positive results. A sample diluent comprising urea can also be used in the process to further reduce the occurrence of nonspecific protein-protein interactions. A diagnostic kit to aid in the detection of anti-rubella IgM antibodies is also disclosed.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: December 30, 2003
    Assignee: Viral Antigens, Inc.
    Inventors: Preston H. Dorsett, Frances I. Byrd, Robert F. Devlin
  • Specificity in the detection of anti-rubella IgM antibodies
    Publication number: 20010055757
    Abstract: This invention particularly discloses an improved immunoassay method for the specific detection of anti-rubella IgM antibodies. This method employs rubella antigens comprising rubella E1 and E2 envelope glycoproteins substantially free of capsid protein. Use of this antigen composition reduces or eliminates nonspecific protein-protein interactions leading to false positive results. A sample diluent comprising urea can also be used in the process to further reduce the occurrence of nonspecific protein-protein interactions. A diagnostic kit to aid in the detection of anti-rubella IgM antibodies is also disclosed.
    Type: Application
    Filed: May 7, 2001
    Publication date: December 27, 2001
    Applicant: VIRAL ANTIGENS, INC.
    Inventors: Preston H. Dorsett, Frances I. Byrd, Robert F. Devlin